Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Exploiting synthetic lethality: The next generation

Clinical development of next generation DDR agents for molecularly-selected tumours


09 Sep 2022


Exploiting synthetic lethality: The next generation


Clinical Research;  Translational Research;  Targeted Therapy;  Cancer Diagnostics;  Staging and Imaging

Tumour Site

Breast Cancer;  Ovarian Cancer;  Prostate Cancer


Timothy Yap


T.A. Yap

Author affiliations

  • Investigational Cancer Therapeutics Dept. (phase I Program), The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US


Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.